October 11, 2011 Program

October 11, 2011

Guest Presenter:

Gerald M. Ostrov served as Chairman and Chief Executive Officer of Bausch & Lomb Incorporated. Mr. Ostrov currently serves as a Consultant of Bausch & Lomb Incorporated. Mr. Ostrov previously retired January 1, 2006 as Company Group Chairman responsible for Johnson & Johnson’s Worldwide Vision Care businesses. Mr. Ostrov was a member of J&J’s Worldwide Consumer and Personal Care Group Operating Committee. He began his career with Johnson & Johnson’s Health Care Division in 1976. In 1982, he left Johnson & Johnson to become Vice President of Marketing for Ciba-Geigy’s Consumer Pharmaceuticals Company. He was named President of Ciba Consumer Pharmaceuticals in 1985 and served in that capacity until rejoining Johnson & Johnson in 1991 as President of the corporation’s Personal Products Company. In 1993, he was promoted to Company Group Chairman and added Northern Europe C&PC products to his responsibilities. In 1995, he became responsible for all Consumer and Personal Care businesses in North America. He assumed Vision Care global current responsibilities in 1998.Mr. Ostrov was Chairman of the Board of Trustees of Middlesex County College (NJ) from 2002 until 2007. He is a Member of the Board of Trustees of the Garden State Arts Foundation (NJ). He was a member of the Cornell University Council. He is a former Board and executive committee member of the Non-Prescription Drug Manufacturers Association. Mr. Ostrov also served on the Johnson & Johnson Corporate Contributions Committee for well over a decade.Mr. Ostrov serves on the Board of the Jewish Federation of Greater Middlesex, and has served on many other local philanthropic boards. He is past and founding President of the East Brunswick (NJ) Education Foundation.Mr. Ostrov earned a Bachelor of Science degree with distinction in Industrial Engineering and Operations Research from Cornell University and holds an M.B.A. from Harvard University.

Presenting Companies:

Adeona Pharmaceuticals

James S. Kuo , M.D., M.B.A., Chairman, CEO and President of Adeona Pharmaceuticals is returning to NYC MedTech for an update.
Adeona is a pharmaceutical company focused on developing innovative medicines for the treatment of serious central nervous system diseases. The Company’s strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Adeona is developing, or has partnered the development of, drug product candidates to treat multiple sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The Company is currently preparing to make the following products commercially available: reaZin™, a prescription medical food for the dietary management of zinc deficiency associated with Alzheimer’s disease, and wellZin™, a homeopathic over-the-counter medicine for reducing the duration and symptoms of the common cold. Adeona also operates Adeona Clinical Laboratory, a wholly owned clinical reference laboratory that provides a broad array of chemistry and microbiology diagnostic tests.
Since February 2007, Dr. Kuo has served Adeona as a member of the Company’s board of directors. In February 2010, Adeona’s board appointed him as Chairman, Chief Executive Officer and President. Previously, Dr. Kuo was Chairman and Chief Executive Officer of Cordex Pharma, a publicly-traded enterprise developing a portfolio of cardiovascular drugs. He launched life science products as Chairman and Chief Executive Officer of BioMicro Systems, a genomic tools company. At Discovery Laboratories, a publicly-traded company developing new surfactant-based respiratory therapeutics, he was a founder and Chief Executive Officer. Dr. Kuo is a founder and board director of Monarch Labs, a privately-held company commercializing medical devices for wound care. He held positions as a licensing executive at Pfizer and Vice President of Business Development at Myriad Genetics. Dr. Kuo was a Managing Director of Venture Analysis with HealthCare Ventures, a venture capital firm with $378 million in funds under management. He served as Chairman of the board of Soligenix, a publicly-traded enterprise developing therapeutic for the life-threatening side effects of cancer therapy and vaccines for certain bioterrorism agents. Currently, he serves as Non-executive Chairman of the board of MSK Pharma, a privately-held company clinically developing Xiaderma, a topical patch to treat carpal tunnel syndrome. Dr. Kuo simultaneously earned an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from the Wharton School of Business. He holds a B.A. in molecular biology from Haverford College.

MSK Pharma

Geraldine P. Kuo, M.D. President & Chief Executive Officer
MSK Pharma is a specialty pharmaceutical company developing innovative medicines for debilitating musculoskeletal diseases and pain conditions. Dr. Kuo has been a Staff Physician for the VA San Diego Healthcare System since 2001. The San Diego VA treats more than 250,000 veterans per year. She has more than 15 years of clinical experience in treating patients with musculoskeletal disorders and help found the musculoskeletal clinic at the VA San Diego Healthcare System. Dr. Kuo earned her B.S. in Biology from Byrn Mawr College and her M.D. from Jefferson Medical College. She received her board certification in Physical Medicine and Rehabilitation and completed her residency at Mount Sinai Medical Center in New York City where she served on the Medical Executive Committee as Chief Resident. She was the recipient of the the Sidney and Elizabeth Licht Award for article of the year in Archives of Physical Medicine and Rehabilitation.

Alzeca Biosciences LLC

Robin Mansukhani, Chief Executive Officer
Alzeca Biosciences is developing a proprietary diagnostic, “ADx”, to detect Alzheimer’s Disease at the earliest stages. In addition, ADx has platform capability for use as an Alzheimer’s drug delivery molecule and as a diagnostic for other neurological disorders (Parkinson’s, Huntington’s, frontotemporal dementia, etc.). Technology development has been supported by the Cure Alzheimer’s Fund, Alliance for NanoHealth, Alzheimer’s Association, and the NIH. Mr. Mansukhani is the CEO of Alzeca Biosciences and was previously a founder of Cense Biosciences, Inc. (now Sensulin — glucose responsive insulin for type I and type II diabetes) and Ecorithm, Inc. (algorithms for diagnosis and optimization of building energy use). He is also Co-founder and Chief Operating Officer ofBlueStamp Engineering, a New York City based, hands on engineering program for both high school and middle school students. Previously, he worked for The Maple Fund, an early stage venture capital firm. Mr. Mansukhani holds a B.S. in Biochemistry from Case Western Reserve University and has served a term in Americorps, where he led health and literacy programs for underserved youth in Cleveland, Ohio.

Wolfgang Daum, President and CEO of Castlewood Surgical, Inc., a Massachusetts-Minnesota-Texas based medical device company in heart surgery. The company’s core product is the Cyclone™ System, which allows the surgeon to eliminate the aortic side-biting clamp in coronary artery bypass grafting (CABG). The Cyclone™ System allows the surgeon to minimize or completely eliminate the aortic clamp while creating a hand-sewn proximal anastomosis with no addition of foreign material.
From mid 2007 to mid 2010, Mr. Wolfgang Daum was President and CEO of Boston Heart Lab Corporation (Framingham, MA) where he built up the company from its beginning to a $6M+ run rate. He raised over $12M in mostly equity financing. Wolfgang Daum attracted and closed under very favorable terms one of the world leading private equity and venture companies (Bain) to continue the company and to transform it into a world leader in heart disease diagnostics. Prior to Boston Heart Lab, Wolfgang was President and CEO of medical device companies BrainVital, Thermonix, CardioTools, and Daum; and relocated from Germany to the US in 2001. Wolfgang holds a M.S. in Physics from Univerity of Gӧttingen and a PhD in Electrical Engineering from Technical University Hamburg-Harburg, both Germany. Wolfgang is a Board member of medical device companies Avancen and PX Spine and angel investor with Beacon and Launchpad Angels in Boston and Keiretsu in NYC and San Francisco.